The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Antibiotics are often thought of as an easy cure to bacterial infections, but they could be fueling an urgent public health ...

US-based diagnostic software company Arkstone Medical Solutions has partnered with Peruvian medical technology company Neslab ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

Researchers have used artificial intelligence to identify 25 new protein compounds that can kill bacteria and fungi, ...

A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

Disperazol Pharma, a leading biotechnology firm that develops compounds that dismantle biofilms of critical Gram—negative pathogens, today announced that it has joined the AMR Industry Alliance. AMR ...

Addresses the significant threat of antimicrobial resistance.

The College of Veterinary Medicine is hosting a public health conference in the Stewart Center about antimicrobial resistance ...